



Amend B/ #11
J 7.12.02

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Gyuris et al.

Serial No: 09/768,183

Filed: January 23, 2001

For: Chimeric Polypeptides of Serum
Albumin and Uses Related Thereto

Attorney Docket No. GPCI-P03-109

Art Unit: 1642

Examiner: Natalie A. Davis

RECEIVED

JUL 11 2002

TECH CENTER 1600/2900

CERTIFICATE OF FACSIMILE UNDER 37 C.F.R. §1.8(a)

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail, postage prepaid, in an envelope addressed to: Commissioner for Patents, United States Patent and Trademark Office, Washington, D.C. 20231 on the date indicated below:

July 2, 2002

Date of Signature
and of Mail Deposit

Joanne Ryan
Joanne Ryan.

Assistant Commissioner of Patents
Washington, D.C. 20231

REPLY UNDER 37 C.F.R. 1.111

Sir:

This amendment is being filed in reply to the outstanding Office Action, mailed April 2, 2002, in connection with the above application. Please enter the following amendments:

In the specification:

Please replace the 2nd paragraph of page 4 with the following paragraph:

B1
The invention also comprises a pharmaceutical composition comprising a chimeric polypeptide as described above, and methods for treating a disease in an organism by administering an effective dose of such a pharmaceutical composition to the organism. In a currently preferred embodiment, a chimeric polypeptide according to the invention comprises a fragment of an angiogenesis-inhibiting protein, such as angiostatin or endostatin, as the heterologous peptide sequence and is capable of inhibiting angiogenesis. For example, a peptide fragment that inhibits angiogenesis and which may be incorporated into a subject polypeptide is RGD (Arg-Gly-Asp), or a